<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18417817</article-id><article-id pub-id-type="pmc">2636123</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_3_179_40355</article-id><article-id pub-id-type="pmid">18417817 </article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Diabetic retinopathy: An update</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Ramandeep</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author"><name><surname>Ramasamy</surname><given-names>Kim</given-names></name><degrees>DNB</degrees></contrib><contrib contrib-type="author"><name><surname>Abraham</surname><given-names>Chandran</given-names></name><degrees>DO</degrees></contrib><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Vishali</given-names></name><degrees>MS</degrees></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gupta</surname><given-names>Amod</given-names></name><degrees>MS</degrees></contrib></contrib-group><aff>Department of Ophthalmology (RS, VG, AG), Postgraduate Institute ofMedical Education and Research, Chandigarh; Aravind Eye Hospital(KR), Madurai, Tamil Nadu; Apollo First Med Hospital (CA), Chennai,Tamil Nadu, India</aff><author-notes><corresp id="cor1">Correspondence to Dr. Amod Gupta, Department of Ophthalmology,Advanced Eye Center, Postgraduate Institute of Medical Education andResearch, Chandigarh - 160 012, India. Email: <email>eyepgi@sify.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>May-Jun</season><year>2008</year></pub-date><volume>56</volume><issue>3</issue><fpage>179</fpage><lpage>188</lpage><history><date date-type="received"><day>09</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2007</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Diabetes mellitus is a major cause of avoidable blindness in both the developing and the developedcountries. Significant technological advances have taken place to improve the diagnostic accuracy of diabeticretinopathy. In the last three decades, the treatment strategies have been revised to include, besides laserphotocoagulation, early surgical interventions and pharmacotherapies.</p></abstract><kwd-group><kwd>Diabetic macular edema</kwd><kwd>diabetic retinopathy</kwd><kwd>laser photocoagulation</kwd><kwd>pars plana vitreous surgery</kwd></kwd-group></article-meta></front><body><p>Diabetes mellitus (DM) is a major cause of avoidable blindness inboth the developing and the developed countries. Patients withdiabetic retinopathy (DR) are 25 times more likely to becomeblind than non-diabetics.<xref ref-type="bibr" rid="ref1">1</xref> Good glycemic control arrests thedevelopment and progression of DR and decreases the visual loss.Technological advances have improved the diagnostic accuracyof screening methods and access of the diabetic patients to thespecialist care. In the last three decades, the treatment strategieshave been revised to include, besides laser photocoagulation,early surgical interventions and pharmacotherapies. The aimof this review was to outline the magnitude of problem of DRin India with the current strategies to manage it.</p><sec sec-type=""><title>Epidemiology</title><p>Majority of the patients have non-insulin-dependent diabetesmellitus (NIDDM) or type 2 diabetes. The prevalence of insulin-dependent diabetes mellitus (IDDM) or type 1 diabetes is 10-15%of the diabetic population. Prevalence of DR in WisconsinEpidemiological Study of Diabetic Retinopathy (WESDR) was50.1%<xref ref-type="bibr" rid="ref2">2</xref> and 54.2% in the diabetes control and complications trial(DCCT) in IDDM<xref ref-type="bibr" rid="ref3">3</xref> and 35-39% in United Kingdom ProspectiveDiabetes Study (UKPDS)<xref ref-type="bibr" rid="ref4">4</xref> in NIDDM. In two studies from SouthIndia, the prevalence rates of DR in NIDDM patients were 34.1%and 37%.<xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref> India has 31.7 million diabeticsubjects at present as per the World Health Organization (WHO) estimates.<xref ref-type="bibr" rid="ref7">7</xref> In theAndhra Pradesh Eye Disease Study (APEDS) of self-reporteddiabetics, the prevalence of DR was 22.4%.<xref ref-type="bibr" rid="ref8">8</xref> In the ChennaiUrban Rural Epidemiology Study (CURES), we evaluated urbansample of diabetic patients and estimated the overall prevalenceof DR as 17.6%.<xref ref-type="bibr" rid="ref9">9</xref></p></sec><sec sec-type=""><title>Prevalence of Visual Impairment Related to Diabetic Retinopathy</title><p>In WESDR, 1.4% of IDDM patients had best-corrected visualacuity of 20/80 to 20/160; and 3.6% had acuity 20/200 or worsein the better eye.<xref ref-type="bibr" rid="ref10">10</xref> In the older-onset group, 3% had vision inthe range 20/80 to 20/160; and 1.6% were 20/200 or worse inthe better eye.<xref ref-type="bibr" rid="ref10">10</xref></p><sec><title>Incidence</title><p>After 10 years of onset of DM, blindness (visual acuity of20/200 or less in the better eye) was 1.8, 4.0 and 4.8% in type 1,insulin-treated type 2 and non-insulin-treated type 2 patients,respectively.<xref ref-type="bibr" rid="ref11">11</xref> In these three groups of patients, the 10-yearincidence visual impairment (loss of 15 letters on a scale of 0-70letters) was 9.4, 37.2 and 23.9%, respectively.<xref ref-type="bibr" rid="ref11">11</xref></p></sec><sec><title>Pathophysiology</title><p>The final metabolic pathway causing DR is unknown. There areseveral theories. Electrolytic imbalance caused by the high aldosereductase levels leads to cell death, especially retinal pericytes,which cause microaneurysm formation.<xref ref-type="bibr" rid="ref12">12</xref> Apart from this,thickening of the capillary basement membrane and increaseddeposition of extracellular matrix components contribute to thedevelopment of abnormal retinal hemodynamics.<xref ref-type="bibr" rid="ref13">13</xref> In diffuse typeof diabetic macular edema (DME), breakdown of the inner blood-retinal barrier results in accumulation of extracellular fluid.<xref ref-type="bibr" rid="ref14">14</xref></p><p>Increased retinal leukostasis has been reported and it causescapillary occlusions and dropout, non-perfusion, endothelialcell damage and vascular leakage due to its less deformablenature.<xref ref-type="bibr" rid="ref15">15</xref></p><p>Currently, there has been a great interest in vasoproliferativefactors, which induce neovascularization. It has been shownthat retinal ischemia stimulates a pathologic neovascularizationmediated by angiogenic factors, such as vascular endothelialgrowth factor (VEGF), which results in proliferative diabeticretinopathy (PDR).<xref ref-type="bibr" rid="ref16">16</xref> VEGFs are released by retinal pigmentepithelium, pericytes and endothelial cells of the retina.</p></sec></sec><sec sec-type=""><title>Risk Factors</title><sec><title>Duration of diabetes</title><p>There is a direct correlation between the frequency and severityof DR and the duration of DM.<xref ref-type="bibr" rid="ref17">17</xref></p></sec><sec><title>Glycemic control</title><p>There is an indirect relationship between the glycemic controland the development and progression of DR. DCCT andEarly Treatment of Diabetic Retinopathy Study (ETDRS) haveconvincingly shown the reduction in risk of progression of DRwith intensive treatment. Decrease in glycosylated hemoglobinlevels was associated with a significant decrease in theprogression of DR as well as the incidence of PDR.<xref ref-type="bibr" rid="ref18">18</xref> Intensivediabetic control leads to reduction in the development andprogression of all diabetic complications.<xref ref-type="bibr" rid="ref19">19</xref></p></sec><sec><title>Age and sex</title><p>The prevalence and severity of DR increases with increasingage in type 1 DM but not in type 2 DM.<xref ref-type="bibr" rid="ref17">17</xref></p></sec><sec><title>Hypertension</title><p>Studies, such as WESDR and UKPDS, suggest that hypertensionincreases the risk and progression of DR and DME. In UKPDS,tight control of blood pressure resulted in 34% reductionin progression of retinopathy with 47% reduced risk ofdeterioration in visual acuity of three lines.</p></sec><sec><title>Nephropathy</title><p>The presence of gross proteinuria at baseline has been reportedto be associated with 95% increased risk of developing DMEamong type I patients in the WESDR. The prevalence of PDR wasmuch higher in patients with persistent microalbuminuria.<xref ref-type="bibr" rid="ref20">20</xref></p></sec><sec><title>Genetics</title><p>In WESDR, patients with HLA DR4 and absent HLA DR3 werefound to be at a greater risk of having PDR. Data from the DCCTalso suggested genetic predisposition to diabetes. However, itis probable that both genetic and environmental factors playa role in the expression of DR.<xref ref-type="bibr" rid="ref21">21</xref></p></sec><sec><title>Serum lipid</title><p>In WESDR, higher total serum cholesterol was associated withincreased risk of having retinal hard exudates. ETDRS hasreported a positive correlation between serum lipids and riskof retinal hard exudates in type 2 DM. Recently, Gupta <italic>et al</italic>.have reported reduction in edema, severity of hard exudatesand subfoveal lipid migration in patients with type 2 diabetesand dyslipidaemia, using a lipid-lowering drug, atorvastatin,as an adjunct to macular photocoagulation.<xref ref-type="bibr" rid="ref22">22</xref></p></sec><sec><title>Anemia</title><p>In ETDRS, low hematocrit levels at baseline were identifiedas independent risk factor for the development of high-riskPDR and severe visual loss. It showed an increased risk ofretinopathy in patients with the hemoglobin level of lessthan 12 g/dl.<xref ref-type="bibr" rid="ref23">23</xref> Anemia-induced retinal hypoxia is speculatedas cause of development of microaneurysms and otherretinopathy changes.<xref ref-type="bibr" rid="ref24">24</xref></p></sec><sec><title>Puberty</title><p>In WESDR, younger onset subjects who were post-menarchalstood a 3.2 times greater risk of developing DR as compared topre-menarchal subjects.<xref ref-type="bibr" rid="ref25">25</xref> Those who were older than 13 yearsat the time of diagnosis were more likely to have retinopathythan those who were younger. The exact mechanism bywhich puberty might exert its effect on the development ofearly retinopathy is not yet understood, but a possible role ofhormonal factors is suspected.</p></sec><sec><title>Socioeconomic status</title><p>Although educational attainment was inversely associated withretinopathy in women in the WESDR, socioeconomic status wasnot associated with increased risk of worsening of retinopathy.Once the level of glycemia is accounted for, social factors havelittle or no influence on this complication of diabetes.<xref ref-type="bibr" rid="ref26">26</xref></p></sec><sec><title>Pregnancy</title><p>Pregnant women with type 1 diabetes have twice the risk ofdeveloping PDR than non-pregnant women. Ideally, youngmothers should be examined for retinopathy before the onsetof pregnancy.<xref ref-type="bibr" rid="ref27">27</xref> The cause of acceleration of DR may be asimple reflection of long duration of diabetes<xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref>or there may be factors, both metabolic and hormonal, that contribute to theoverall deterioration of DR in the pregnant patient.</p></sec></sec><sec sec-type=""><title>Clinical Features of Diabetic Retinopathy</title><sec><title>Non-proliferative and proliferative diabetic retinopathy</title><p>Non-proliferative diabetic retinopathy (NPDR) is characterizedby the presence of: (i) microaneurysms, which are the firstclinically detectable lesions of DR located in the inner nuclearlayer of the retina, (ii) dot and blot hemorrhages, which arelocated in the middle retinal layers, (iii) hard exudates, whichare located between the inner plexiform and inner nuclearlayer of the retina, (iv) vascular changes such as beading,looping and sausage like segmentation of the veins, (v) cottonwool spots, also called soft exudates or nerve fiber infarcts,result from capillary occlusion of the retinal nerve fiber layer,(vi) intraretinal microvascular abnormalities (IRMA), whichare dilated capillaries that seem to function as collateralchannels, frequently seen adjacent to the areas of capillaryclosure, (vii) retinal edema characterized by accumulation offluid between the outer plexiform layer and inner nuclear layer,which may later involve the entire layers of the retina.</p><p>In the natural course, approximately 50% of patients withvery severe NPDR progress to PDR within 1 year.<xref ref-type="bibr" rid="ref30">30</xref> PDR ischaracterized by the presence of neovascularization. New vesselsmay proliferate on the optic nerve head (new vessels at disc -NVD) and along the course of the major vascular arcades (newvessels elsewhere - NVE). The new vessels mostly grow along theposterior hyaloid and sudden vitreous contraction may result inrupture of these fragile vessels. When the vitreous detachmentoccurs, the new vessels are pulled anteriorly along with theunderlying retina, resulting in tractional retinal detachment. Onthe other hand, vitreous might detach completely without anypull on the retina and new vessels regress, thus resulting in thedevelopment of an end-stage disease.</p><p>ETDRS<xref ref-type="bibr" rid="ref31">31</xref> has classified NPDR into mild, moderate, severeand very severe and PDR into early PDR and high-risk PDR. Thisis as follows:<list list-type="alpha-upper"><list-item><p>Mild NPDR: Presence of at least one microaneurysm,definition not met for B, C, D, E, or F.</p></list-item><list-item><p>Moderate NPDR: Hemorrhages and/or microaneurysmsmore than standard photo 2A, presence of soft exudates,venous beading, IRMA definitely present, definition notmet for C, D, E, or F.</p></list-item><list-item><p>Severe NPDR: Hemorrhages and/or microaneurysms morethan standard photo 2A in all four quadrants, or venousbeading in two or more quadrants, or IRMA &#x0003e; standardphoto 8A in at least one quadrant, definition not met for D, E, or F.</p></list-item><list-item><p>Very severe NPDR: Any two or more of the changes seenin severe NPDR, definition not met for E, or F.</p></list-item><list-item><p>Early PDR: Presence of new vessels, definition not metfor F.</p></list-item><list-item><p>High-risk PDR: Includes any of the following characteristics -neovascularization of disc (NVD) &#x0003e; 1/3<sup>rd</sup> to 1/4<sup>th</sup> discdiameter, NVD &#x0003c; 1/3<sup>rd</sup> to 1/4<sup>th</sup> disc diameter with vitreous/pre-retinal hemorrhage, NVE with vitreous/pre-retinalhemorrhage. High-risk characteristics (HRC) were definedby DRS, as the patient, if not treated urgently, is at a highrisk of severe visual loss.</p></list-item></list></p><p>International Clinical Diabetic Retinopathy Disease Severityscale<xref ref-type="bibr" rid="ref32">32</xref> has developed an easily understandable scale to classifyNPDR. This scale is based on findings observed upon dilatedophthalmoscopy, which includes no apparent retinopathy - noabnormalities, mild NPDR - microaneurysms only, moderateNPDR - more than just microaneurysms but less than severeNPDR and severe NPDR includes any of the following such as20 intraretinal hemorrhages in each of four quadrants, definitevenous beading in two or more quadrants, prominent IRMAin one or more quadrants and no signs of PDR.</p></sec><sec><title>Diabetic macular edema</title><p>Macular edema or retinal thickening is an importantmanifestation of DR and the most common cause of moderatevisual loss. The intraretinal fluid comes from leakingmicroaneurysms or diffuses from capillary incompetence areas.Sometimes the pockets of fluid are so large that they can beseen as cystoid macular edema (CME).</p><p>Diabetic macular edema is retinal thickening within twodisc diameters of the center of macula. DME patients werecategorized into clinically significant macular edema (CSME)or non-CSME by ETDRS. CSME includes any one of thefollowing lesions:</p><p><list list-type="order"><list-item><p>Retinal thickening at or within 500 microns from the centerof macula.</p></list-item><list-item><p>Hard exudates at or within 500 microns from the center ofmacula associated with thickening of the adjacent retina.</p></list-item><list-item><p>An area or areas of retinal thickening at least one disc areain size, at least a part of which is within one disc diameterof the center of macula.</p></list-item></list></p><p>International clinical diabetic macular edema severity scale<xref ref-type="bibr" rid="ref32">32</xref>has devised a simpler classification for the understanding ofgeneral ophthalmologist. The severity scale includes no DMEpresent (no retinal thickening or hard exudates in the posteriorpole), DME present (retinal thickening or hard exudates inthe posterior pole). It is further classified as mild, moderate orsevere depending upon the severity of macular edema.</p></sec><sec><title>Ancillary investigations</title><p>Diabetic retinopathy is essentially a clinical diagnosis. Slitlamp biomicroscopy, dilated fundus evaluation with a directophthalmoscope and indirect ophthalmoscope or contact/non-contact slit lamp biomicroscopic examination are essential in thediagnosis of DR. However, several ancillary investigations arerequired to aid the diagnosis, plan and execute the treatmentand to document the lesions for research purposes. Stereoscopicfundus photographs may be required for research purposes andare especially useful for the assessment of macular edema.</p></sec><sec><title>Fundus fluorescein angiography</title><p>Fundus fluorescein angiography (FFA) is not required foridentification of lesions like NVD or NVE, as these lesionsare identified clinically. FFA is used to classify and treat DMEinto focal and diffuse variety. It also aids in diagnosis of CME.ETDRS has documented the angiographic risk factors forprogression of NPDR to PDR.<xref ref-type="bibr" rid="ref33">33</xref> These include widespreadcapillary loss, capillary dilatation and fluorescein leakage asdocumented on FFA. It aids in differentiating IRMAs fromnew vessels. IRMAs do not leak on FFA while new vesselsleak profusely.</p></sec><sec><title>Optical coherence tomography</title><p>Optical coherence tomography (OCT) generates cross-sectionalimage of the retina, which is comparable to histologicalsections. OCT is more sensitive than clinical fundus evaluationin diagnosing CSME. OCT provides us with quantitativemeasurement of thickness in the posterior pole area withreasonable accuracy,<xref ref-type="bibr" rid="ref34">34</xref>-<xref ref-type="bibr" rid="ref36">36</xref> thus aiding in establishingthe diagnosis of CSME.<xref ref-type="bibr" rid="ref37">37</xref> The repeatability and accuracy of OCTis very helpful in assessing and prognosticating the responseof CSME to any treatment.<xref ref-type="bibr" rid="ref37">37</xref>-<xref ref-type="bibr" rid="ref39">39</xref></p><p>Diabetic macular edema is classified into different morphologicalpatterns based on OCT.<xref ref-type="bibr" rid="ref40">40</xref>-<xref ref-type="bibr" rid="ref42">42</xref> In a study it has beenshown that OCT findings correlate reasonably with FFA features.<xref ref-type="bibr" rid="ref43">43</xref></p></sec><sec><title>Non-mydriatic fundus photography</title><p>Digital non-mydriatic camera is being increasingly usedfor screening patients that can be subsequently reviewedby the experts to determine the need for referral to anophthalmologist.</p></sec></sec><sec sec-type=""><title>Management</title><sec><title>Laser photocoagulation</title><p>Laser photocoagulation is indicated in CSME and in PDR withHRC.<xref ref-type="bibr" rid="ref44">44</xref>-<xref ref-type="bibr" rid="ref46">46</xref> Various factors known to worsen retinopathymay initiate treatment in severe NPDR and early PDR without HRCsuch as pregnancy, nephropathy, cardiac failure, coronary arterydisease, cataract surgery and Yag capsulotomy, uncontrolledblood sugars, recent initiation of insulin in NIDDM patientwith longstanding uncontrolled blood sugars, poor patientfollow-up.<xref ref-type="bibr" rid="ref47">47</xref></p><sec><title>Laser photocoagulation for diabetic macular edema</title><p>Diabetic macular edema is treated by coagulatingmicroaneurysms around the fovea and applying treatmentwithin the center of circinate rings. The ETDRS used directfocal treatment to individual microaneurysms and a gridpattern to areas of diffuse leakage and capillary non-perfusion as identified on FFA.<xref ref-type="bibr" rid="ref48">48</xref> Modified grid patterns oflaser treatment either alone or in combination with focaltreatment have been described. Adequate treatment ofDME can be achieved without FFA.<xref ref-type="bibr" rid="ref49">49</xref> However, a projectedangiogram during laser photocoagulation may improve theprecision of treatment.<xref ref-type="bibr" rid="ref50">50</xref> ETDRS demonstrated that treatmentprevented moderate visual loss (loss of 15 letters or threelines on the standard ETDRS visual acuity chart) in 24%eyes, compared to 12% in untreated controls, at 3 years.<xref ref-type="bibr" rid="ref30">30</xref>,<xref ref-type="bibr" rid="ref46">46</xref>,<xref ref-type="bibr" rid="ref51">51</xref>Residual macular edema may be re-treated 4-6 months after the initial treatment.</p></sec><sec><title>Laser photocoagulation for proliferative diabetic retinopathy</title><p>Diabetic retinopathy study (DRS) recommended full scattertechnique to HRC eyes.<xref ref-type="bibr" rid="ref46">46</xref> Panretinal photocoagulation (PRP)can cause macular edema or lead to worsening of existingedema, hence macular edema is treated prior to commencementof panretinal treatment.<xref ref-type="bibr" rid="ref52">52</xref>-<xref ref-type="bibr" rid="ref54">54</xref></p><p>The DRS found that PRP prevented severe visual loss by over50% at 2 and 4 years of follow-up.<xref ref-type="bibr" rid="ref30">30</xref>,<xref ref-type="bibr" rid="ref45">45</xref>,<xref ref-type="bibr" rid="ref46">46</xref> When eyes with high-risk factors were considered, severe visual loss was found in11% treated eyes and in 26% untreated controls. The visualbenefit was apparent from 16 months of the study, lastedthroughout the study period and was sustained for severalyears after the study.</p><p>Additional treatment is performed when there is residualneovascularization and areas of skipped treatment after PRP.Burns are placed over skipped areas, between previous laserscars, more centrally towards the optic disc and macula andin areas of neovascularization.<xref ref-type="bibr" rid="ref55">55</xref></p><p>The argon green (514 nm), frequency doubled Nd:YAG(532 nm), krypton red (647 nm), diode (810 nm) and tunabledye (560-640 nm) lasers are all reported to be effective in thetreatment of DR. The choice of wavelength is not critical froma clinical point of view and does not have a major effect onthe visual outcome.<xref ref-type="bibr" rid="ref56">56</xref> Focal laser treatment with light laserphotocoagulation and subthreshold micropulse diode laser arealso emerging.<xref ref-type="bibr" rid="ref57">57</xref> A new type of scanning laser such as patternedscanning laser photocoagulation (PASCAL) has been described,which is capable of giving multiple spots with a single footpedal depression.<xref ref-type="bibr" rid="ref58">58</xref></p></sec></sec><sec><title>Pars plana vitreous surgery in diabetic retinopathy</title><p>Pars plana vitrectomy (PPV) has been used extensively to treatvarious complications of DR. The major indications are non-clearing vitreous hemorrhage, macula-involving or macula-threatening tractional retinal detachment and combinedtractional-rhegmatogenous detachment.<xref ref-type="bibr" rid="ref59">59</xref> Less commonindications are macular edema with a thickened and tautposterior hyaloid, macular heterotropia, epiretinal membrane,severe premacular hemorrhage, neovascular glaucoma withcloudy media<xref ref-type="bibr" rid="ref59">59</xref> and ghost cell glaucoma.<xref ref-type="bibr" rid="ref60">60</xref></p><p>Diabetic retinopathy vitrectomy study (DRVS) randomized370 eyes with extensive neovascularization and visual acuityof 20/400 or better into two groups of early vitrectomy orobservation alone.<xref ref-type="bibr" rid="ref61">61</xref> The results indicate that such patientsprobably do not benefit from early vitrectomy. They shouldbe observed closely so that vitrectomy, when needed, canbe undertaken promptly. DRVS<xref ref-type="bibr" rid="ref62">62</xref> also studied diabetic eyeswith vitreous hemorrhage and visual acuity less than 5/200for 6 months and randomized these into two groups of thosewho received immediate surgery and those whose surgerywas deferred for another 6 months. The study recommendedearly surgery in type 1 diabetic patients, more so in bilateralcases and one-eyed patients. It is important to note that DRVSnoticed loss of light perception (approximately 25%) whoreceived immediate vitrectomy.</p><p>Over the course of time, with the improvement in instruments andsurgical techniques, the spectrum of indications for vitrectomyhas been extended to include recalcitrant DME with or withouttaut posterior hyaloid membrane.<xref ref-type="bibr" rid="ref59">59</xref> Vitrectomy was found to beuseful in eyes with diffuse macular edema with vitreomaculartraction due to taut posterior hyaloid membrane.<xref ref-type="bibr" rid="ref63">63</xref> The removalof various local growth factors, such as VEGF, angiotensin andinflammatory cytokines (IL-6)<xref ref-type="bibr" rid="ref64">64</xref>,<xref ref-type="bibr" rid="ref65">65</xref> in vitreoussurgery, helps to retard progression of DME. Ikeda <italic>et al</italic>.<xref ref-type="bibr" rid="ref66">66</xref> suggested thatthe removal of the barrier between vitreous cavity and retina mightlead to improved fluid diffusion from the retinal tissue. Variousstudies suggest that the presence of tangential vitreomaculartractional forces combined with the local presence of a numberof cytokines and growth factors contributes to the developmentof DME and removal of these benefited macular edema.<xref ref-type="bibr" rid="ref67">67</xref>-<xref ref-type="bibr" rid="ref71">71</xref> Various studies have reported better outcome in DME whenpeeling of internal limiting membrane (ILM) is combined withPPV.<xref ref-type="bibr" rid="ref72">72</xref>-<xref ref-type="bibr" rid="ref73">73</xref> Removal of massive hard exudates with PPVfrom the fovea has lead to mixed response in terms of improvement ofvision in low-vision patients<xref ref-type="bibr" rid="ref74">74</xref>-<xref ref-type="bibr" rid="ref75">75</xref>[Figures <xref ref-type="fig" rid="F1">1</xref> and <xref ref-type="fig" rid="F2">2</xref>].</p></sec><sec><title>Newer strategies in diabetic retinopathy management</title><sec><title>Systemic control</title><p>DCCT<xref ref-type="bibr" rid="ref16">16</xref> showed that in intensively treated group, the risk ofonset of retinopathy was reduced by 76%, risk of progressionof retinopathy by 63%, risk of development of CSME by23% and the need for laser treatment by 56% compared tothe conventional group. This benefit persisted even 4 yearsafter initiation of intensive therapy.<xref ref-type="bibr" rid="ref76">76</xref> Similar results wereseen in type 2 diabetic patients by UKPDS,<xref ref-type="bibr" rid="ref77">77</xref> which showedthat in intensively treated group the risk of progression ofretinopathy was reduced by 17%, risk of development ofvitreous hemorrhage by 23%, need for laser treatment by 29%and risk of development of legal blindness by 16% comparedto the conventional group. Further DCCT<xref ref-type="bibr" rid="ref78">78</xref> highlighted thatafter initiation of intensive insulin therapy there may be aninitial transient worsening, however eventually these patientsfare much better in the long run. Recent studies showed thedirect relation of higher levels of glycosylated hemoglobin withpersistent CSME<xref ref-type="bibr" rid="ref79">79</xref> and inadequate response of PDR to PRP.<xref ref-type="bibr" rid="ref80">80</xref></p><p>The WESDR found a 17% prevalence of hypertension at baselineand a 25% incidence after 10 years in type 1 diabetics.<xref ref-type="bibr" rid="ref81">81</xref> UKPDS<xref ref-type="bibr" rid="ref82">82</xref> showed that in intensive blood pressure control group, therewas a 34% (<italic>P</italic> = 0.0004) and 47% (<italic>P</italic> = 0.004) reduction in risk ofDR progression and moderate visual acuity loss, respectively,compared to the control group after a median follow-up of8.4 years.</p><p>Anemia has been found to be an independent risk factor forthe development of high-risk proliferative PDR.<xref ref-type="bibr" rid="ref83">83</xref>,<xref ref-type="bibr" rid="ref84">84</xref>Beneficial effect of anemia treatment in patients of DR has beendocumented.<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref85">85</xref>,<xref ref-type="bibr" rid="ref86">86</xref></p><p>ETDRS<xref ref-type="bibr" rid="ref87">87</xref> identified elevated levels of serum cholesterol andlow-density lipoproteins (LDL) as independent risk factorsfor the development of hard exudates, which is a major riskfactor leading to subfoveal fibrosis. The beneficial role ofstatins such as atorvastatin (HMG-CoA reductase inhibitor)as an adjunct to standard treatment in patients with DME hasbeen documented.<xref ref-type="bibr" rid="ref22">22</xref></p><p>Various cross-sectional and longitudinal studies have reporteda relationship between proteinuria and retinopathy.<xref ref-type="bibr" rid="ref88">88</xref>-<xref ref-type="bibr" rid="ref89">89</xref> The presence and severity of DR is an indicator of the risk of grossproteinuria and conversely, proteinuria predicts presence of PDR.A beneficial effect of ACE inhibitors and angiotensin receptorantagonists on both proteinuria (micro- or macroalbuminuria)and retinopathy, even in normotensive patients, has beenshown.<xref ref-type="bibr" rid="ref90">90</xref>-<xref ref-type="bibr" rid="ref91">91</xref> A few studies have reported a beneficialeffect of dialysis and renal transplant on DR with improved stabilizationand response of retinopathy to laser treatment.<xref ref-type="bibr" rid="ref92">92</xref>,<xref ref-type="bibr" rid="ref93">93</xref></p><p>In a small pilot study, it has been shown that optimal metaboliccontrol of all the above factors led to a significant reduction inmacular thickness and a trend towards visual improvementafter 6 weeks even without focal laser photocoagulation.<xref ref-type="bibr" rid="ref94">94</xref></p></sec><sec><title>Pharmacotherapy</title><p>Pharmacological agents can affect the metabolic pathwayat various levels so that the diabetes complications such asretinopathy, neuropathy and nephropathy can be prevented.Most of the diabetes-related complications, such as macularedema and neovascularization, occur secondary to the releaseof the growth factors in response to retinal ischemia fromalterations in the structure and cellular composition of themicrovasculature.<xref ref-type="bibr" rid="ref95">95</xref>,<xref ref-type="bibr" rid="ref96">96</xref></p><p>VEGF is produced by the pigment epithelial cells, pericytesand endothelial cells of the retina in response to hypoxia.<xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref95">95</xref> VEGF aids inflammation by inducing intracellular adhesionmolecule-1 (ICAM-1) expression and leukocyte adhesion.<xref ref-type="bibr" rid="ref97">97</xref>Specific inhibition of VEGF activity is able to preventretinal neovascularization and associated blood flowabnormalities.</p><p>Corticosteroids have been demonstrated to inhibit theexpression of the VEGF gene. Nauck <italic>et al</italic>.<xref ref-type="bibr" rid="ref98">98</xref> demonstratedthat corticosteroids abolished the induction of VEGF by thepro-inflammatory mediators, such as pigment-derived growthfactor (PDGF) and platelet-activating factor (PAF), in a time- anddose-dependent manner. Thus, corticosteroids downregulateVEGF production and possibly prevent breakdown of theblood-retinal barrier. Similarly, steroids have antiangiogenicproperties possibly due to attenuation of the effects of VEGF.Both of these steroid effects have been utilized as intravitrealor posterior subtenon injection to cause temporary reductionof edema even prior to laser photocoagulation in DMEand neovascularization in various studies<xref ref-type="bibr" rid="ref99">99</xref>,<xref ref-type="bibr" rid="ref100">100</xref>[Figures <xref ref-type="fig" rid="F3">3</xref>-<xref ref-type="fig" rid="F6">Figure 6</xref>].Intravitreal implants (Fluocinolone acetonide) may permit thedrug action for longer duration.<xref ref-type="bibr" rid="ref101">101</xref></p><p>Human clinical studies on effect of intravitreal administeredanti-VEGF aptamer, pegaptanib sodium (Macugen) andantibodies, ranibizumab (Leucentis) and bevacizumab(Avastin) on DME has shown favorable results.<xref ref-type="bibr" rid="ref102">102</xref>-<xref ref-type="bibr" rid="ref105">105</xref> Off-label use of intravitreal anti-VEGF drug bevacizumab (Avastin;Genentech Inc., South San Francisco, CA, USA) has been shownto be useful in causing regression of neovascularization inPDR<xref ref-type="bibr" rid="ref106">106</xref>,<xref ref-type="bibr" rid="ref107">107</xref> [Figures <xref ref-type="fig" rid="F7">7</xref>-<xref ref-type="fig" rid="F9">9</xref>]. It has also been used as a preoperativeadjunct to calm down the fibrovascular proliferation beforevitrectomy.<xref ref-type="bibr" rid="ref108">108</xref></p><p>Protein kinase C (PKC) beta has an important role in regulatingendothelial cell permeability<xref ref-type="bibr" rid="ref109">109</xref> and is an important signalingcomponent for VEGF.<xref ref-type="bibr" rid="ref110">110</xref> The orally administered PKC-&#x003b2;isoform-selective inhibitor ruboxistaurin (RBX) in subjects withmoderately severe to very severe NPDR was well-toleratedand reduced the risk of visual loss but did not prevent DRprogression.<xref ref-type="bibr" rid="ref111">111</xref> RBX treatment was associated with a reductionof retinal vascular leakage in eyes with DME.<xref ref-type="bibr" rid="ref112">112</xref></p><p>Aldose reductase plays an important role in polyol pathway,which generates sorbitol during hyperglycemia. Sorbitolaccumulation, in turn, disrupts the osmotic balance, thusdestroying the retinal cells such as pericytes.<xref ref-type="bibr" rid="ref113">113</xref> Aldose reductaseinhibitors (ARI), such as sorbinil, ponalrestat and tolrestat, haveshown decrease in capillary cell death, microaneurysm countand fluorescein leakage.<xref ref-type="bibr" rid="ref114">114</xref>-<xref ref-type="bibr" rid="ref117">117</xref> However, clinicaltrials of ARI had little therapeutic success.</p><p>Trials with long acting octreotide (a somatostatin analog andgrowth hormone/IGF-1 antagonist) (Sandostatin; Novartis, AG,Basel, Switzerland) delayed the time to progression ofretinopathy, but had no effect on visual acuity or progressionto macular edema.<xref ref-type="bibr" rid="ref118">118</xref></p><p>Cyclooxygenase (COX)-2 enzymes cause angiogenesisthrough prostanoid, which stimulates expression of VEGFand subsequently endothelial cell proliferation. COX-2inhibitors (APHS and etodolac) have shown prevention ofneovascularization in experimental conditions.<xref ref-type="bibr" rid="ref119">119</xref> Humantrials evaluating effects of the COX-2 inhibitor, celecoxib,are still underway. Angiotensin-converting enzyme (ACE)inhibitors and angiotensin II receptor blockers (ARB), apartfrom the hypotensive effects, stimulate both VEGF andcorresponding receptor expression. In experimental models,ACE inhibitors have been shown to inhibit VEGF expression.Clinically, the results of ACE inhibitors are variable.<xref ref-type="bibr" rid="ref120">120</xref>,<xref ref-type="bibr" rid="ref121">121</xref>Among ARBs, in a small study, losartan was shown to haveno beneficial effect on DME.<xref ref-type="bibr" rid="ref122">122</xref></p></sec></sec></sec><sec sec-type=""><title>Screening for Diabetic Retinopathy</title><sec><title>Ophthalmoscopy</title><p>Ophthalmoscopy is the most commonly used technique toscreen for DR. When performed by an ophthalmologist, thespecificity of direct and indirect ophthalmoscopy was high,but the sensitivity was low (34-50%), particularly for earlyretinopathy, in comparison to 7-field stereo photographicassessment.<xref ref-type="bibr" rid="ref123">123</xref></p></sec><sec><title>Digital imaging</title><p>Digital imaging makes fundus photography easier and morewidely accessible. It may be used to obtain fundus imagesthrough non-dilated pupils. Mydriasis is usually necessaryin older patients. Single-field fundus photography withinterpretation by trained readers could serve as a screeningtool to identify patients with DR.<xref ref-type="bibr" rid="ref124">124</xref></p></sec><sec><title>Telemedical screening</title><p>A major advantage of digital technologies is the ability totransmit images to a centralized reading center for grading.The Joslin Diabetes Center in Boston has developed theJoslin Vision Network (JVN), which includes a remoteimaging system, a centralized grading center and a datastorage system. Implementing retinal imaging technologyin a primary care setting results in a significant increase inthe rate of DR surveillance and in the rate of laser treatmentfor DR.</p></sec></sec><sec sec-type=""><title>Conclusions</title><p>There were 31.7 million diabetics in India in year 2000 witha projection to reach 79.4 million by year 2030. Developingstrategies for screening of population for early detectionof DR is engaging attention of several groups in India. Thepresent review outlines the magnitude of the problem in India,conventional and current strategies to manage the potentiallyblinding complications of DM. While laser photocoagulationand pars plana vitreous surgery remain the standards ofcare, recent successful use of several molecules is bringingabout a paradigm shift in favor of pharmacotherapy. Theophthalmologists should encourage a good comprehensivesystemic control for better outcomes.</p></sec></body><back><fn-group><fn><p>Source of Support: Nil</p></fn><fn><p>Conflict of Interest: None declared</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="book"><collab>National society to prevent blindness</collab><year>1980</year><publisher-loc>New York</publisher-loc><publisher-name>National society to prevent blindness</publisher-name><fpage>1</fpage><lpage>46</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Airey</surname><given-names>M</given-names></name><name><surname>Baxter</surname><given-names>H</given-names></name></person-group><article-title>Epidemiology of diabetic retinopathy and macular edema: A systematic review</article-title><source>Eye</source><year>2004</year><volume>18</volume><fpage>963</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">15232600</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malone</surname><given-names>JI</given-names></name><name><surname>Morrison</surname><given-names>AD</given-names></name><name><surname>Pavan</surname><given-names>PR</given-names></name><name><surname>Cuthbertson</surname><given-names>DD</given-names></name></person-group><article-title>Diabetic Control and Complications Trial: Prevalence and significance of retinopathy in subjects with type 1 diabetes ofless than 5 years duration screened for the diabetes control and complications trial</article-title><source>Diabetes Care</source><year>200</year><volume>124</volume><fpage>522</fpage><lpage>6</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohner</surname><given-names>EM</given-names></name><name><surname>Aldington</surname><given-names>SJ</given-names></name><name><surname>Stratton</surname><given-names>IM</given-names></name></person-group><article-title>United Kingdom Prospective Diabetes Study, 30: Diabetic retinopathy at diagnosis of non-insulin-dependent diabetesmellitus and associated risk factors</article-title><source>Arch Ophthalmol</source><year>1998</year><volume>116</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">9514482</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rema</surname><given-names>M</given-names></name><name><surname>Ponnaiya</surname><given-names>M</given-names></name><name><surname>Mohan</surname><given-names>V</given-names></name></person-group><article-title>Prevalence of retinopathy in non insulin dependent diabetes mellitus at a diabetes centre in SouthernIndia</article-title><source>Diabetes Res Clin Pract</source><year>1996</year><volume>34</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">8968688</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>RA</given-names></name></person-group><article-title>Diabetic eye disease in southern India</article-title><source>Community Eye Health</source><year>1996</year><volume>9</volume><fpage>56</fpage><lpage>8</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>S</given-names></name><name><surname>Roglic</surname><given-names>G</given-names></name><name><surname>Green</surname><given-names>A</given-names></name></person-group><article-title>Global prevalence of diabetes, estimates for the year 2000 and projections for 2030</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1047</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15111519</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandona</surname><given-names>L</given-names></name><name><surname>Dandona</surname><given-names>R</given-names></name><name><surname>Naduvilath</surname><given-names>TJ</given-names></name></person-group><article-title>Population based assessment of diabetic retinopathy in an urban population in southern India</article-title><source>Br J Ophthalmol</source><year>1999</year><volume>83</volume><fpage>937</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">10413697</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rema</surname><given-names>M</given-names></name><name><surname>Premkumar</surname><given-names>S</given-names></name><name><surname>Anitha</surname><given-names>B</given-names></name></person-group><article-title>Prevalence of diabetic retinopathy in urban India: The Chennai Urban Rural Epidemiology Study (CURES) eyestudy</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>2328</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15980218</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BEK</given-names></name><name><surname>Moss</surname><given-names>SE</given-names></name></person-group><article-title>Visual impairment in diabetes</article-title><source>Ophthalmology</source><year>1984</year><volume>91</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">6709312</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>SE</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name></person-group><article-title>Ten-year incidence of visual loss in a diabetic population</article-title><source>Ophthalmology</source><year>1994</year><volume>101</volume><fpage>1061</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">8008348</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubawara</surname><given-names>T</given-names></name><name><surname>Cogan</surname><given-names>DG</given-names></name></person-group><article-title>Retinal vascular patterns VI: Mural cells of the retinal capillaries</article-title><source>Arch Ophthalmol</source><year>1962</year><volume>69</volume><fpage>492</fpage><lpage>502</lpage></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>JR</given-names></name><name><surname>Kilo</surname><given-names>C</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Scarpelli</surname><given-names>DG</given-names></name><name><surname>Migahi</surname><given-names>DG</given-names></name></person-group><article-title>Extracellular matrix changes in diabetes mellitus</article-title><source>Comparative pathobiology of major age-related diseases</source><year>1984</year><publisher-loc>New York</publisher-loc><publisher-name>Liss</publisher-name><fpage>269</fpage><lpage>88</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferris</surname><given-names>FL</given-names><suffix>III</suffix></name><name><surname>Patz</surname><given-names>A</given-names></name></person-group><article-title>Macular edema: A complication of diabetic retinopathy</article-title><source>Surv Ophthalmol</source><year>1984</year><volume>28</volume><fpage>452</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">6379946</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Khosrof</surname><given-names>S</given-names></name><name><surname>Bursell</surname><given-names>SE</given-names></name></person-group><article-title>Prevention of leukostasis and vascular change in streptozotocin induced diabetic retinopathy via intercellular adhesionmolecule-1 inhibition</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>10836</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">10485912</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Avery</surname><given-names>RL</given-names></name><name><surname>Arrigg</surname><given-names>PG</given-names></name><name><surname>Keyt</surname><given-names>BA</given-names></name><name><surname>Jampel</surname><given-names>HD</given-names></name><name><surname>Shah</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinaldisorders</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><fpage>1480</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7526212</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Moss</surname><given-names>SE</given-names></name></person-group><article-title>The Wisconsin Epidemiologic Study of Diabetic Retinopathy, II: Prevalence and high risk of diabetic retinopathy when ageat diagnosis is less than 30 years</article-title><source>Arch Ophthalmol</source><year>1984</year><volume>102</volume><fpage>520</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6367724</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><collab>The Diabetes Control and Complications Trial Research Group</collab><article-title>The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin -dependent diabetes mellitus</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>977</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">8366922</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><collab>EDIC research group</collab><article-title>Retinopathy and nephropathy in type 1 diabetes patients four years after trial of intensive therapy</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>381</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10666428</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathiesen</surname><given-names>ER</given-names></name><name><surname>Ronn</surname><given-names>B</given-names></name><name><surname>Storm</surname><given-names>B</given-names></name></person-group><article-title>The natural course of microalbuminuria in insulin-dependent diabetes: A 10-year prospective study</article-title><source>Diabetes Med</source><year>1995</year><volume>12</volume><fpage>482</fpage><lpage>7</lpage></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><collab>Diabetes Control and Complications Trial Research Group</collab><article-title>Clustering of long-term complications in families with diabetes in the diabetes control and complicationstrial</article-title><source>Diabetes</source><year>1997</year><volume>46</volume><fpage>1829</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">9356033</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Thapar</surname><given-names>S</given-names></name><name><surname>Bhansali</surname><given-names>A</given-names></name></person-group><article-title>Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema</article-title><source>Am J Ophthalmol</source><year>2004</year><volume>137</volume><fpage>675</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15059707</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Fisher</surname><given-names>MR</given-names></name><name><surname>Gangnon</surname><given-names>RE</given-names></name></person-group><article-title>Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment DiabeticRetinopathy Study Report #18</article-title><source>Invest Ophthalmol Vis Sci</source><year>1998</year><volume>39</volume><fpage>233</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">9477980</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Bhansali</surname><given-names>A</given-names></name></person-group><article-title>Spontaneous closure of microaneurysms in diabetic retinopathy with treatment of co-existing anemia</article-title><source>Br J Ophthalmol</source><year>2005</year><volume>89</volume><fpage>248</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15665369</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Moss</surname><given-names>SE</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name></person-group><article-title>Is menarche associated with diabetic retinopathy?</article-title><source>Diabetes Care</source><year>1990</year><volume>13</volume><fpage>1034</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2209299</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Jensen</surname><given-names>SC</given-names></name><name><surname>Moss</surname><given-names>SE</given-names></name></person-group><article-title>The relation of socioeconomic factors to the incidence of proliferative diabetic retinopathy and loss ofvision</article-title><source>Ophthalmology</source><year>1994</year><volume>101</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">8302566</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Moss</surname><given-names>SE</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name></person-group><article-title>Effect of pregnancy on progression of diabetic retinopathy</article-title><source>Diabetes Care</source><year>1990</year><volume>13</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">2404715</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvat</surname><given-names>M</given-names></name><name><surname>Maclean</surname><given-names>H</given-names></name><name><surname>Goldberg</surname><given-names>L</given-names></name><name><surname>Crock</surname><given-names>GW</given-names></name></person-group><article-title>Diabetic retinopathy in pregnancy: A 12-year prospective survey</article-title><source>Br J Ophthalmol</source><year>1980</year><volume>64</volume><fpage>398</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">7387964</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moloney</surname><given-names>JB</given-names></name><name><surname>Drury</surname><given-names>MI</given-names></name></person-group><article-title>The effect of pregnancy in the natural course of diabetic retinopathy</article-title><source>Am J Ophthalmol</source><year>1982</year><volume>93</volume><fpage>745</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">6178293</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Early photocoagulation for diabetic retinopathy: ETDRS report no 9</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><fpage>766</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">2062512</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><fpage>823</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">2062515</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>CP</given-names></name><name><surname>Ferris</surname><given-names>FL</given-names><suffix>3rd</suffix></name><name><surname>Klein</surname><given-names>RE</given-names></name><name><surname>Lee</surname><given-names>PP</given-names></name><name><surname>Agardh</surname><given-names>CA</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><etal/></person-group><article-title>Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales</article-title><source>Ophthalmology</source><year>2003</year><volume>110</volume><fpage>1677</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">13129861</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Fluorescein angiographic risk factors for progression of diabetic retinopathy: ETDRS report number 13</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><fpage>834</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">2062516</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadda</surname><given-names>SR</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Walsh</surname><given-names>AC</given-names></name><name><surname>Richine</surname><given-names>L</given-names></name><name><surname>Dougall</surname><given-names>J</given-names></name><name><surname>Cortez</surname><given-names>R</given-names></name><etal/></person-group><article-title>Errors in retinal thickness measurements obtained by optical coherence tomography</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>285</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16406542</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polito</surname><given-names>A</given-names></name><name><surname>Del Borrello</surname><given-names>M</given-names></name><name><surname>Polini</surname><given-names>G</given-names></name><name><surname>Furlan</surname><given-names>F</given-names></name><name><surname>Isola</surname><given-names>M</given-names></name><name><surname>Bandello</surname><given-names>F</given-names></name></person-group><article-title>Diurnal variation in clinically significant diabetic macular edema measured by the Stratus OCT</article-title><source>Retina</source><year>2006</year><volume>26</volume><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16395133</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goebel</surname><given-names>W</given-names></name><name><surname>Franke</surname><given-names>R</given-names></name></person-group><article-title>Retinal thickness in diabetic retinopathy: Comparison of optical coherence tomography, the retinal thickness analyzerand fundus photography</article-title><source>Retina</source><year>2006</year><volume>26</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16395139</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panozzo</surname><given-names>G</given-names></name><name><surname>Gusson</surname><given-names>E</given-names></name><name><surname>Parolini</surname><given-names>B</given-names></name><name><surname>Mercanti</surname><given-names>A</given-names></name></person-group><article-title>Role of OCT in the diagnosis and follow up of diabetic macular edema</article-title><source>Semin Ophthalmol</source><year>2003</year><volume>18</volume><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">14566626</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luttrull</surname><given-names>JK</given-names></name><name><surname>Spink</surname><given-names>CJ</given-names></name></person-group><article-title>Serial optical coherence tomography of sub threshold diode laser micro pulse photocoagulation for diabetic macularedema</article-title><source>Ophthalmic Surg Lasers Imaging</source><year>2006</year><volume>37</volume><fpage>370</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17017196</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>JI</given-names></name><name><surname>Hykin</surname><given-names>PG</given-names></name><name><surname>Schadt</surname><given-names>M</given-names></name><name><surname>Luong</surname><given-names>V</given-names></name><name><surname>Fitzke</surname><given-names>F</given-names></name><name><surname>Gregor</surname><given-names>ZJ</given-names></name></person-group><article-title>Pars plana vitrectomy for diabetic macular edema: OCT and functional correlations</article-title><source>Eye</source><year>2006</year><volume>20</volume><fpage>674</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16244647</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otani</surname><given-names>T</given-names></name><name><surname>Kishi</surname><given-names>S</given-names></name><name><surname>Maruyama</surname><given-names>Y</given-names></name></person-group><article-title>Patterns of diabetic macular edema with optical coherence tomography</article-title><source>Am J Ophthalmol</source><year>1999</year><volume>127</volume><fpage>688</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">10372879</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>BY</given-names></name><name><surname>Smith</surname><given-names>SD</given-names></name><name><surname>Kaiser</surname><given-names>PK</given-names></name></person-group><article-title>Optical coherence tomographic patterns of diabetic macular edema</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>142</volume><fpage>405</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16935584</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panozzo</surname><given-names>G</given-names></name><name><surname>Parolini</surname><given-names>B</given-names></name><name><surname>Gusson</surname><given-names>E</given-names></name><name><surname>Mercanti</surname><given-names>A</given-names></name><name><surname>Pinackatt</surname><given-names>S</given-names></name><name><surname>Bertoldo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Diabetic macular edema: An OCT-based classification</article-title><source>Semin Ophthalmol</source><year>2004</year><volume>19</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15658007</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name><name><surname>Ham</surname><given-names>DI</given-names></name></person-group><article-title>The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significantdiabetic macular edema</article-title><source>Am J Ophthalmol</source><year>2004</year><volume>137</volume><fpage>313</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">14962423</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Photocoagulation for diabetic macular edema: ETDRS Report Number 1</article-title><source>Arch Ophthalmol</source><year>1985</year><volume>103</volume><fpage>1796</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">2866759</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><collab>Diabetic Retinopathy Study Research Group</collab><article-title>Preliminary report on effects of photocoagulation therapy</article-title><source>Am J Ophthalmol</source><year>1976</year><volume>81</volume><fpage>383</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">944535</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><collab>Diabetic Retinopathy Study Research Group</collab><article-title>Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of the Diabetic Retinopathy Study(DRS) findings: DRS Report Number 8</article-title><source>Ophthalmology</source><year>1981</year><volume>88</volume><fpage>583</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">7196564</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>MD</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Ryan</surname><given-names>SJ</given-names></name><name><surname>Schachat</surname><given-names>AP</given-names></name><name><surname>Murphy</surname><given-names>RB</given-names></name></person-group><source>Proliferative diabetic retinopathy</source><year>1994</year><volume>Vol 2</volume><publisher-loc>Retina St. Louis</publisher-loc><publisher-name>CV Mosby Co</publisher-name><fpage>1320</fpage><lpage>59</lpage></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: ETDRS Report Number2</article-title><source>Ophthalmology</source><year>1987</year><volume>94</volume><fpage>761</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">3658348</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu el</surname><given-names>Asrar</given-names></name><name><surname>Morse</surname><given-names>PH</given-names></name></person-group><article-title>Laser photocoagulation control of diabetic macular edema without fluorescein angiography</article-title><source>Br J Ophthalmol</source><year>1991</year><volume>75</volume><fpage>97</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1995053</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kylstra</surname><given-names>JA</given-names></name><name><surname>Brown</surname><given-names>JC</given-names></name><name><surname>Jaffe</surname><given-names>GJ</given-names></name></person-group><article-title>The importance of fluorescein angiography in planning laser treatment of diabetic macular edema</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>2068</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">10571339</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>ETDRS Report Number 4</article-title><source>Int Ophthalmol Clin</source><year>1987</year><volume>27</volume><fpage>265</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">3692708</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><collab>Early Treatment Diabetic Retinopathy Study Research Group</collab><article-title>Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: ETDRS Report Number3</article-title><source>Int Ophthalmol Clin</source><year>1987</year><volume>27</volume><fpage>254</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">3692707</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><collab>Diabetic Retinopathy Study Research Group</collab><article-title>Macular edema in Diabetic Retinopathy Study (DRS) patients: DRS Report Number 12</article-title><source>Ophthalmology</source><year>1987</year><volume>94</volume><fpage>754</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">3658347</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><collab>Diabetic Retinopathy Study Research Group</collab><article-title>Factors influencing the development of visual loss in advanced diabetic retinopathy: DRS Report Number10</article-title><source>Invest Ophthalmol Vis Sci</source><year>1985</year><volume>26</volume><fpage>983</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">2409053</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="book"><collab>Diabetic Retinopathy Study Research Group</collab><article-title>Photocoagulatingtreatment of Proliferative diabetic retinopathy: A short report of long-range results. DRS report number 4</article-title><source>Proceeding of the 10th Congress of the international diabetes federation</source><year>1980</year><publisher-loc>Amsterdam</publisher-loc><publisher-name>Excerpta Medica</publisher-name></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bressler</surname><given-names>SB</given-names></name></person-group><article-title>Does wavelength matter when photocoagulating eyes with macular degeneration or diabetic retinopathy</article-title><source>Arch Ophthalmol</source><year>1993</year><volume>111</volume><fpage>177</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">8431153</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandello</surname><given-names>F</given-names></name><name><surname>Pognuz</surname><given-names>R</given-names></name><name><surname>Polito</surname><given-names>A</given-names></name><name><surname>Pirracchio</surname><given-names>A</given-names></name></person-group><article-title>Diabetic macular edema: Classification, medical and laser therapy</article-title><source>Semin Ophthalmol</source><year>2003</year><volume>18</volume><fpage>251</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15513012</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenkranz</surname><given-names>MS</given-names></name><name><surname>Yellachich</surname><given-names>D</given-names></name><name><surname>Andersen</surname><given-names>DE</given-names></name><name><surname>Wiltberger</surname><given-names>MW</given-names></name><name><surname>Mordaunt</surname><given-names>D</given-names></name></person-group><article-title>Semi automated patterned scanning laser for retinal photocoagulation</article-title><source>Retina</source><year>2006</year><volume>26</volume><fpage>370</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16508446</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenblatt</surname><given-names>BJ</given-names></name><name><surname>Benson</surname><given-names>WE</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Rosenblatt</surname><given-names>BJ</given-names></name><name><surname>Benson</surname><given-names>WE</given-names></name></person-group><article-title>Diabetic retinopathy</article-title><source>Ophthalmology</source><volume>vol 2</volume><edition>2nd ed</edition><fpage>877</fpage><lpage>86</lpage></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spraul</surname><given-names>CN</given-names></name><name><surname>Grossniklais</surname><given-names>HE</given-names></name></person-group><article-title>Vitreous hemorrhage</article-title><source>Surv Ophthalmol</source><year>1997</year><volume>42</volume><fpage>3</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">9265701</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><collab>Diabetic retinopathy Vitrectomy Study Research Group</collab><article-title>Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: Results of a randomizedtrial. Diabetic retinopathy vitrectomy study report</article-title><source>Ophthalmology</source><year>1998</year><volume>95</volume><fpage>1307</fpage><lpage>20</lpage></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><collab>Diabetic retinopathy Vitrectomy Study Research Group</collab><article-title>Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: Two-year results of a randomized trial:Diabetic retinopathy vitrectomy study report 2</article-title><source>Ophthalmology</source><year>1998</year><volume>95</volume><fpage>1307</fpage><lpage>20</lpage></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massin</surname><given-names>P</given-names></name><name><surname>Duguid</surname><given-names>G</given-names></name><name><surname>Erginay</surname><given-names>A</given-names></name></person-group><article-title>Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>135</volume><fpage>167</fpage><lpage>77</lpage></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funastu</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name></person-group><article-title>Relation of diabetic macular edema to cytokines and posterior vitreous detachment</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>135</volume><fpage>321</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12614749</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funastu</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name></person-group><article-title>Vitreous levels of IL 6 and VGEF are related to diabetic macular edema</article-title><source>Ophthalmology</source><year>2003</year><volume>135</volume><fpage>1690</fpage><lpage>6</lpage></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Katano</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name></person-group><article-title>Attached posterior hyaloid membrane and the pathogenesis of honeycombed cystoids macular edema in patients withdiabetes</article-title><source>Am J Ophthalmol</source><year>1999</year><volume>127</volume><fpage>478</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10218713</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>H</given-names></name><name><surname>Abrams</surname><given-names>G</given-names></name><name><surname>Blumenkranz</surname><given-names>M</given-names></name><name><surname>Campo</surname><given-names>R</given-names></name></person-group><article-title>Vitrectomy for diabetic macular edema associated with posterior hyaloidal traction</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>753</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1594222</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>D</given-names></name><name><surname>Vinores</surname><given-names>S</given-names></name><name><surname>Campochiaro</surname><given-names>P</given-names></name></person-group><article-title>Macular edema: The role of soluble mediators</article-title><source>Br J Ophthalmol</source><year>2000</year><volume>84</volume><fpage>542</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10781524</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name></person-group><article-title>Posterior vitreous precortical pocket</article-title><source>Arch Ophthalmol</source><year>1990</year><volume>108</volume><fpage>979</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">2369358</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pendergast</surname><given-names>SD</given-names></name><name><surname>Hassan</surname><given-names>TS</given-names></name><name><surname>Williams</surname><given-names>GA</given-names></name></person-group><article-title>Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>130</volume><fpage>178</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">11004291</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachi</surname><given-names>N</given-names></name><name><surname>Ogino</surname><given-names>N</given-names></name></person-group><article-title>Vitrectomy for diffuse macular edema in cases of diabetic retinopathy</article-title><source>Am J Ophthalmol</source><year>1996</year><volume>122</volume><fpage>258</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8694095</pub-id></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heiji</surname><given-names>EC</given-names></name><name><surname>Hendrikse</surname><given-names>F</given-names></name><name><surname>Kessels</surname><given-names>AG</given-names></name><name><surname>Paul</surname><given-names>J</given-names></name><name><surname>Derhaag</surname><given-names>FM</given-names></name></person-group><article-title>Vitrectomy results in diabetic macular edema without evident vitreomacular traction</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2001</year><volume>239</volume><fpage>264</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">11450490</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandofer</surname><given-names>A</given-names></name><name><surname>Messmer</surname><given-names>E</given-names></name><name><surname>Ulbig</surname><given-names>M</given-names></name><name><surname>Kampik</surname><given-names>A</given-names></name></person-group><article-title>Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and inner limitingmembrane</article-title><source>Retina</source><year>2000</year><volume>20</volume><fpage>126</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10783944</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takagi</surname><given-names>H</given-names></name><name><surname>Otani</surname><given-names>A</given-names></name><name><surname>Kiryu</surname><given-names>J</given-names></name><name><surname>Ogura</surname><given-names>Y</given-names></name></person-group><article-title>New surgical approach for removing massive foveal of sub macular hard exudates in diabetic macular edema</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>249</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">9951473</pub-id></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaya</surname><given-names>K</given-names></name><name><surname>Suzuki Y Mizutani</surname><given-names>H</given-names></name></person-group><article-title>Long-term results of vitrectomy for removal of sub macular hard exudates in patients with diabeticmaculopathy</article-title><source>Retina</source><year>2004</year><volume>24</volume><fpage>23</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15076940</pub-id></element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><collab>The Diabetes Control and Complications Trial/Epidemiologyof Diabetes Interventions and Complications Research Group</collab><article-title>Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensivetherapy</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><fpage>381</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10666428</pub-id></element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab><article-title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk ofcomplications in patients with type 2 diabetes (UKPDS 33)</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>837</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">9742976</pub-id></element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><collab>Diabetes Control and Complications Trial Research Group</collab><article-title>Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial</article-title><source>Arch Ophthalmol</source><year>1998</year><volume>116</volume><fpage>874</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">9682700</pub-id></element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Do</surname><given-names>DV</given-names></name><name><surname>Shah</surname><given-names>SM</given-names></name><name><surname>Sung</surname><given-names>JU</given-names></name><name><surname>Haller</surname><given-names>JA</given-names></name><name><surname>Nguyen</surname><given-names>QD</given-names></name></person-group><article-title>Persistent diabetic macular edema is associated with elevated hemoglobin A1c</article-title><source>Am J Ophthalmol</source><year>2005</year><volume>139</volume><fpage>620</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">15808156</pub-id></element-citation></ref><ref id="ref80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotoula</surname><given-names>MG</given-names></name><name><surname>Koukoulis</surname><given-names>GN</given-names></name><name><surname>Zintzaras</surname><given-names>E</given-names></name><name><surname>Karabatsas</surname><given-names>CH</given-names></name><name><surname>Chatzoulis</surname><given-names>DZ</given-names></name></person-group><article-title>Metabolic control of diabetes is associated with an improved response of diabetic retinopathy to panretinalphotocoagulation</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>2454</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16186279</pub-id></element-citation></ref><ref id="ref81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Lee</surname><given-names>KE</given-names></name></person-group><article-title>The incidence of hypertension in insulin-dependent diabetes</article-title><source>Arch Intern Med</source><year>1996</year><volume>156</volume><fpage>622</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8629873</pub-id></element-citation></ref><ref id="ref82"><label>82</label><element-citation publication-type="journal"><collab>UK Prospective Diabetes Study Group</collab><article-title>Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS38</article-title><source>BMJ</source><year>1998</year><volume>317</volume><fpage>703</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">9732337</pub-id></element-citation></ref><ref id="ref83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Fisher</surname><given-names>MR</given-names></name><name><surname>Gangnon</surname><given-names>RE</given-names></name></person-group><article-title>Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment DiabeticRetinopathy Study Report #18</article-title><source>Invest Ophthalmol Vis Sci</source><year>1998</year><volume>39</volume><fpage>233</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">9477980</pub-id></element-citation></ref><ref id="ref84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>Q</given-names></name><name><surname>Keinanen-Kiukaanniemi</surname><given-names>S</given-names></name><name><surname>Laara</surname><given-names>E</given-names></name></person-group><article-title>The relationship between hemoglobin levels and diabetic retinopathy</article-title><source>J Clin Epidemiol</source><year>1997</year><volume>50</volume><fpage>153</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9120508</pub-id></element-citation></ref><ref id="ref85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorb</surname><given-names>SR</given-names></name></person-group><article-title>Anemia and diabetic retinopathy</article-title><source>Am J Ophthalmol</source><year>1985</year><volume>100</volume><fpage>434</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">4037031</pub-id></element-citation></ref><ref id="ref86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>EA</given-names></name><name><surname>Brown</surname><given-names>CD</given-names></name><name><surname>Berman</surname><given-names>DH</given-names></name></person-group><article-title>Erythropoietin in diabetic macular edema and renal insufficiency</article-title><source>Am J Kidney Dis</source><year>1995</year><volume>26</volume><fpage>202</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7611253</pub-id></element-citation></ref><ref id="ref87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name><name><surname>Ferris</surname><given-names>FL</given-names></name></person-group><article-title>Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy: Early Treatment DiabeticRetinopathy Study (ETDRS) Report 22</article-title><source>Arch Ophthalmol</source><year>1996</year><volume>114</volume><fpage>1079</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8790092</pub-id></element-citation></ref><ref id="ref88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estacio</surname><given-names>RO</given-names></name><name><surname>McFarling</surname><given-names>E</given-names></name><name><surname>Biggerstaff</surname><given-names>S</given-names></name></person-group><article-title>Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM</article-title><source>Am J Kidney Dis</source><year>1998</year><volume>31</volume><fpage>947</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">9631838</pub-id></element-citation></ref><ref id="ref89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>CE</given-names></name><name><surname>Chachati</surname><given-names>A</given-names></name><name><surname>Christensen</surname><given-names>CK</given-names></name></person-group><article-title>Microalbuminuria: An early marker of renal involvement in diabetes</article-title><source>Uremia Invest</source><year>1985</year><volume>9</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">3915933</pub-id></element-citation></ref><ref id="ref90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravid</surname><given-names>M</given-names></name><name><surname>Brosh</surname><given-names>D</given-names></name><name><surname>Levi</surname><given-names>Z</given-names></name><name><surname>Bar-Dayan</surname><given-names>Y</given-names></name><name><surname>Ravid</surname><given-names>D</given-names></name><name><surname>Rachmani</surname><given-names>R</given-names></name></person-group><article-title>Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetesmellitus: A randomized, controlled trial</article-title><source>Ann Intern Med</source><year>1998</year><volume>128</volume><fpage>982</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9625684</pub-id></element-citation></ref><ref id="ref91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravid</surname><given-names>M</given-names></name><name><surname>Savin</surname><given-names>H</given-names></name><name><surname>Jutrin</surname><given-names>I</given-names></name><name><surname>Bental</surname><given-names>T</given-names></name><name><surname>Katz</surname><given-names>B</given-names></name><name><surname>Lishner</surname><given-names>M</given-names></name></person-group><article-title>Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria innormotensive type II diabetic patients</article-title><source>Ann Intern Med</source><year>1993</year><volume>118</volume><fpage>577</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">8452322</pub-id></element-citation></ref><ref id="ref92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokuyama</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name></person-group><article-title>Effects of haemodialysis on diabetic macular leakage</article-title><source>Br J Ophthalmol</source><year>2000</year><volume>84</volume><fpage>1397</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">11090481</pub-id></element-citation></ref><ref id="ref93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>IA</given-names></name><name><surname>Ilango</surname><given-names>B</given-names></name><name><surname>Sells</surname><given-names>RA</given-names></name><name><surname>Wong</surname><given-names>D</given-names></name></person-group><article-title>Stabilization of diabetic retinopathy following simultaneous pancreas and kidney transplant</article-title><source>Br J Ophthalmol</source><year>2000</year><volume>84</volume><fpage>736</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">10873985</pub-id></element-citation></ref><ref id="ref94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Abhiramamurthy</surname><given-names>V</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Bhansali</surname><given-names>A</given-names></name></person-group><article-title>Effect of Multifactorial Intervention on Diabetic Macular Edema</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>463</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16443911</pub-id></element-citation></ref><ref id="ref95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>L</given-names></name><name><surname>Avery</surname><given-names>R</given-names></name><name><surname>Arrigg</surname><given-names>P</given-names></name></person-group><article-title>Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinaldisorders</article-title><source>N Eng J Med</source><year>1194</year><volume>331</volume><fpage>1480</fpage><lpage>7</lpage></element-citation></ref><ref id="ref96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonelli-Orlidge</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>D&#x02032;Amore</surname><given-names>P</given-names></name></person-group><article-title>Influence of pericytes on capillary endothelial cell growth</article-title><source>Am Rev Respir Dis</source><year>1989</year><volume>140</volume><fpage>1129</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">2679268</pub-id></element-citation></ref><ref id="ref97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>S</given-names></name><name><surname>Usui</surname><given-names>T</given-names></name><name><surname>Yamashiro</surname><given-names>K</given-names></name></person-group><article-title>VEGF164 is pro inflammatory in the diabetic retina</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>2155</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">12714656</pub-id></element-citation></ref><ref id="ref98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>Eickleberg</surname><given-names>O</given-names></name><name><surname>Weiland</surname><given-names>H</given-names></name><name><surname>Stulz</surname><given-names>P</given-names></name><etal/></person-group><article-title>Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids</article-title><source>Am J Respir Cell Mol Biol</source><year>1997</year><volume>16</volume><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">9115750</pub-id></element-citation></ref><ref id="ref99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>J</given-names></name><name><surname>Degenring</surname><given-names>R</given-names></name></person-group><article-title>Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macularedema</article-title><source>Klin Monatsbl Augenheikd</source><year>2002</year><volume>219</volume><fpage>429</fpage><lpage>32</lpage></element-citation></ref><ref id="ref100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martidis</surname><given-names>A</given-names></name><name><surname>Duker</surname><given-names>J</given-names></name><name><surname>Greenberg</surname><given-names>P</given-names></name></person-group><article-title>Intravitreal triamcinolone for refractory diabetic macular edema</article-title><source>Ophthalmology</source><year>2002</year><volume>109</volume><fpage>920</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11986098</pub-id></element-citation></ref><ref id="ref101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>P</given-names></name><name><surname>Levy</surname><given-names>B</given-names></name><name><surname>Comstock</surname><given-names>T</given-names></name></person-group><article-title>Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multicenter clinicaltrial</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>1020</fpage><lpage>7</lpage></element-citation></ref><ref id="ref102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Altaweel</surname><given-names>M</given-names></name><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Bressler</surname><given-names>NM</given-names></name><name><surname>D&#x02032;Amico</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>A phase II randomized double-masked trial of pegaptanib: An anti-vascular endothelial growth factor aptamer, fordiabetic macular edema</article-title><source>Ophthalmology</source><year>2005</year><volume>112</volume><fpage>1747</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16154196</pub-id></element-citation></ref><ref id="ref103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>QD</given-names></name><name><surname>Tatlipinar</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>SM</given-names></name><name><surname>Haler</surname><given-names>JA</given-names></name></person-group><article-title>Vascular endotherlial growth factor is a critical stimulus for diabetic macular edema</article-title><source>Am J Ophthamol</source><year>2006</year><volume>142</volume><fpage>961</fpage><lpage>9</lpage></element-citation></ref><ref id="ref104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>DW</given-names></name><name><surname>Heier</surname><given-names>JS</given-names></name><name><surname>Topping</surname><given-names>TM</given-names></name><name><surname>Duker</surname><given-names>JS</given-names></name></person-group><article-title>A pilot study of multiple intravitreal injections of ranibizumab in patients with center involving clinicallysignificant macular edema</article-title><source>Ophthalmology</source><year>2006</year><volume>11113</volume><fpage>1706</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17011952</pub-id></element-citation></ref><ref id="ref105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haritoglou</surname><given-names>C</given-names></name><name><surname>Kook</surname><given-names>D</given-names></name><name><surname>Neubauer</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name></person-group><article-title>Intravitreal Bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema</article-title><source>Retina</source><year>2006</year><volume>26</volume><fpage>999</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">17151486</pub-id></element-citation></ref><ref id="ref106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spaide</surname><given-names>RF</given-names></name><name><surname>Fisher</surname><given-names>YL</given-names></name></person-group><article-title>Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreoushemorrhage</article-title><source>Retina</source><year>2006</year><volume>26</volume><fpage>275</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16508426</pub-id></element-citation></ref><ref id="ref107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>JO</given-names><suffix>3rd</suffix></name><name><surname>Nixon</surname><given-names>PA</given-names></name><name><surname>White</surname><given-names>MF</given-names></name></person-group><article-title>Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabeticretinopathy</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>142</volume><fpage>685</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17011869</pub-id></element-citation></ref><ref id="ref108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name></person-group><article-title>Use of intravitreal Bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severeproliferative diabetic retinopathy</article-title><source>Retina</source><year>2006</year><volume>26</volume><fpage>699</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">16829817</pub-id></element-citation></ref><ref id="ref109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagpala</surname><given-names>P</given-names></name><name><surname>Malik</surname><given-names>AB</given-names></name><name><surname>Vuong</surname><given-names>PT</given-names></name><name><surname>Lum</surname><given-names>H</given-names></name></person-group><article-title>Protein kinase C b1 over expression augments phorbol ester-induced increase in endothelial permeability</article-title><source>J Cell Physiol</source><year>1996</year><volume>166</volume><fpage>249</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">8591984</pub-id></element-citation></ref><ref id="ref110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>P</given-names></name><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>ZY</given-names></name><name><surname>Park</surname><given-names>DJ</given-names></name><name><surname>Robinson</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Characterization of vascular endothelial growth factor&#x02032;s effect on the activation of protein kinase C, itsisoforms and endothelial cell growth</article-title><source>J Clin Invest</source><year>1996</year><volume>98</volume><fpage>2018</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">8903320</pub-id></element-citation></ref><ref id="ref111"><label>111</label><element-citation publication-type="journal"><collab>The PKC-DRS Study Group</collab><article-title>The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabeticretinopathy: Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomizedclinical trial</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>2188</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">15983221</pub-id></element-citation></ref><ref id="ref112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strom</surname><given-names>C</given-names></name><name><surname>Sander</surname><given-names>B</given-names></name><name><surname>Klemp</surname><given-names>K</given-names></name><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Lund-Anderson</surname><given-names>H</given-names></name><name><surname>Larsen</surname><given-names>M</given-names></name></person-group><article-title>Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macularedema</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><fpage>3855</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16186374</pub-id></element-citation></ref><ref id="ref113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speiser</surname><given-names>PP</given-names></name><name><surname>Gittelsohn</surname><given-names>AM</given-names></name><name><surname>Patz</surname><given-names>A</given-names></name></person-group><article-title>Studies on diabetic retinopathy, III: Influence of diabetes on intramural pericytes</article-title><source>Arch Ophthalmol</source><year>1968</year><volume>80</volume><fpage>332</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">4174771</pub-id></element-citation></ref><ref id="ref114"><label>114</label><element-citation publication-type="journal"><collab>Sorbinil Retinopathy Trial Research Group</collab><article-title>A randomized trial of sorbinil: An aldose reductase inhibitor, in diabetic retinopathy</article-title><source>Arch Ophthalmol</source><year>1990</year><volume>108</volume><fpage>1234</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">2119168</pub-id></element-citation></ref><ref id="ref115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tromp</surname><given-names>A</given-names></name><name><surname>Hooymans</surname><given-names>JM</given-names></name><name><surname>Barendsen</surname><given-names>BC</given-names></name><name><surname>van Doormaal</surname><given-names>JJ</given-names></name></person-group><article-title>The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy</article-title><source>Doc Ophthalmol</source><year>1991</year><volume>78</volume><fpage>153</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1790735</pub-id></element-citation></ref><ref id="ref116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arauz-Pacheco</surname><given-names>C</given-names></name><name><surname>Ramirez</surname><given-names>LC</given-names></name><name><surname>Pruneda</surname><given-names>L</given-names></name><name><surname>Sanborn</surname><given-names>GE</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Raskin</surname><given-names>P</given-names></name></person-group><article-title>The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy</article-title><source>J Diabetes Compl</source><year>1992</year><volume>6</volume><fpage>131</fpage><lpage>7</lpage></element-citation></ref><ref id="ref117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Gerven</surname><given-names>JM</given-names></name><name><surname>Boot</surname><given-names>JP</given-names></name><name><surname>Lemkes</surname><given-names>HH</given-names></name><name><surname>van Best</surname><given-names>JA</given-names></name></person-group><article-title>Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blindtrial</article-title><source>Doc Ophthalmol</source><year>1994</year><volume>87</volume><fpage>355</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">7851219</pub-id></element-citation></ref><ref id="ref118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>M</given-names></name><name><surname>Mames</surname><given-names>R</given-names></name><name><surname>Fitzgerald</surname><given-names>C</given-names></name></person-group><article-title>The efficacy of octeoride in the therapy of severe nonproliferative and early proliferative diabeticretinopathy</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><fpage>504</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10857943</pub-id></element-citation></ref><ref id="ref119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sennlaub</surname><given-names>F</given-names></name><name><surname>Valamanesh</surname><given-names>F</given-names></name><name><surname>Vezquer-tello</surname><given-names>A</given-names></name></person-group><article-title>COX-2 in human and experimental ischemic proliferative retinopathy</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>198</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">12821538</pub-id></element-citation></ref><ref id="ref120"><label>120</label><element-citation publication-type="journal"><collab>UK prospective diabetes study group</collab><article-title>Efficacy of atenolol and captopril in reducing risk of macro vascular and micro vascular complication in type 2diabetes. UKPDS 39</article-title><source>BMJ</source><year>1998</year><volume>317</volume><fpage>713</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">9732338</pub-id></element-citation></ref><ref id="ref121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>R</given-names></name><name><surname>Kelly</surname><given-names>D</given-names></name><name><surname>Cox</surname><given-names>A</given-names></name></person-group><article-title>Angiotensin converting enzyme inhibition reduces retinal over expression of VEGF and hyper permeability in experimentaldiabetes</article-title><source>Diabetologia</source><year>2000</year><volume>43</volume><fpage>1360</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11126403</pub-id></element-citation></ref><ref id="ref122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>ST</given-names></name><name><surname>Bek T Poulsen</surname><given-names>PL</given-names></name><name><surname>Hove</surname><given-names>MN</given-names></name><name><surname>Rehling</surname><given-names>M</given-names></name><name><surname>Mogensen</surname><given-names>CE</given-names></name></person-group><article-title>Effects of losartan on diabetic maculopathy in type 2 diabetic patients: A randomized, double-maskedstudy</article-title><source>J Intern Med</source><year>2003</year><volume>254</volume><fpage>147</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">12859696</pub-id></element-citation></ref><ref id="ref123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DY</given-names></name><name><surname>Blumenkranz</surname><given-names>MS</given-names></name><name><surname>Brothers</surname><given-names>RJ</given-names></name><name><surname>Grosvenor</surname><given-names>DM</given-names></name></person-group><article-title>The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote imageinterpretation for diabetic retinopathy screening: A comparison with ophthalmoscopy and standardized mydriatic colorphotography</article-title><source>Am J Ophthalmol</source><year>2002</year><volume>134</volume><fpage>204</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12140027</pub-id></element-citation></ref><ref id="ref124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>GA</given-names></name><name><surname>Scott</surname><given-names>IU</given-names></name><name><surname>Haller</surname><given-names>JA</given-names></name><name><surname>Maguire</surname><given-names>AM</given-names></name><name><surname>Marcus</surname><given-names>D</given-names></name><name><surname>McDonald</surname><given-names>R</given-names></name></person-group><article-title>Single field fundus photography for diabetic retinopathy screening: A report by American academy ofOphthalmology</article-title><source>Ophthalmology</source><year>2004</year><volume>111</volume><fpage>1055</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15121388</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>Case 1: Fundus photograph of the right eye showing massive peripapillary fibrovascular proliferation with vitreous hemorrhage</p></caption><alt-text>Figure 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-179-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Case 1: Fundus photograph of the same eye after pars plana vitreous surgery</p></caption><alt-text>Figure 2</alt-text><graphic xlink:href="IndianJOphthalmol-56-179-g002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Case 2: Fundus photograph of the right eye shows severenon-proliferative diabetic retinopathy with macular edema and hardexudates threatening the foveal center</p></caption><alt-text>Figure 3</alt-text><graphic xlink:href="IndianJOphthalmol-56-179-g003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Case 2: Optical coherence tomography line scan showsretinal thickening with spongy retina and cystoid changes in the centeralong with subfoveal serous detachment</p></caption><alt-text>Figure 4</alt-text><graphic xlink:href="IndianJOphthalmol-56-179-g004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p>Case 2: Patient underwent grid laser photocoagulation2 weeks after receiving 40-mg subtenon triamcinolone injection. Threemonths post-laser treatment, fundus photograph of the same eyeshows severe non-proliferative diabetic retinopathy without significantmacular edema</p></caption><alt-text>Figure 5</alt-text><graphic xlink:href="IndianJOphthalmol-56-179-g005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><p>Case 2: Three months post-laser treatment, opticalcoherence tomography line scan shows mild retinal thickening withspongy retina</p></caption><alt-text>Figure 6</alt-text><graphic xlink:href="IndianJOphthalmol-56-179-g006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><p>Case 3: Fundus photograph of the right eye shows severenon-proliferative diabetic retinopathy with macular edema (a). Latephase of angiogram shows early microaneurysmal leakage with diffuselate leakage with cystoid changes (b). Optical coherence tomographyline scan shows retinal thickening with spongy retina with cystoidchanges in the center (c)</p></caption><alt-text>Figure 7</alt-text><graphic xlink:href="IndianJOphthalmol-56-179-g007"/></fig><fig id="F8" position="float"><label>Figure 8</label><caption><p>Case 3: Fundus photograph of the same eye six weeksafter receiving 1.25 mg/0.05 ml intravitreal Avastin shows decreasedmacular edema (a). Late phase of angiogram shows reduction in diffuseleakage 6 weeks after Avastin (b). Optical coherence tomography linescan shows marked reduction in retinal thickening and restoration offoveal contour at 6 weeks after Avastin (c)</p></caption><alt-text>Figure 8</alt-text><graphic xlink:href="IndianJOphthalmol-56-179-g008"/></fig><fig id="F9" position="float"><label>Figure 9</label><caption><p>Case 3: Ten weeks after Avastin, fundus photograph of thesame eye shows reappearance of macular edema (a). Late phase ofangiogram shows reappearance of diffuse leakage at 10 weeks afterAvastin (b). Optical coherence tomography line scan at 10 weeks afterAvastin shows increase in retinal thickening, showing that the effect ofanti-VEGF drugs Avastin is transient (c)</p></caption><alt-text>Figure 9</alt-text><graphic xlink:href="IndianJOphthalmol-56-179-g009"/></fig></floats-group></article>